Haemonetics has completed its acquisition of OpSens, a cardiology-focused firm that features proprietary optical technology. The company acquired all outstanding OpSens shares for CAD $2.90 a share, representing equity value of about $255 million.

Haemonetics完成了对OpSens的收购，OpSens是一家专注于心脏病的公司，拥有专有光学技术。该公司以每股2.90加元的价格收购了OpSens的所有已发行股份，股权价值约为2.55亿美元。

The company also increased fiscal year 2024 GAAP revenue growth guidance from 7-9% to 8-10%. Haemonetics expects OpSens to provide $55-65 million in revenue and be slightly accretive to earnings per diluted share, contributing about $0.10 to $0.15 in adjusted earnings per share.

该公司还将2024财年GAAP收入增长指导从7-9%提高到8-10%。Haemonetics预计OpSens将提供5500万至6500万美元的收入，并略微增加稀释每股收益，调整后每股收益约为0.10至0.15美元。

The deal was first revealed two months ago.

这笔交易是两个月前首次披露的。

OpSens’ core offerings include SavvyWire, which the company says is the world’s first, only three-in-one guidewire for TAVR (transcatheter aortic valve replacement) procedures that acts as both a pacing and pressure monitoring wire, and OptoWire, a pressure guidewire that measures Fractional Flow Reserve (FFR) and diastolic pressure ratio (dPR) to help diagnose and treat coronary artery disease. .

OpSens的核心产品包括SavvyWire和OptoWire，SavvyWire是世界上第一个用于TAVR（经导管主动脉瓣置换术）手术的三合一导丝，该导丝同时充当起搏和压力监测线，测量血流储备分数（FFR）和舒张压比（dPR）以帮助诊断和治疗冠状动脉疾病的压力导丝。。。

OpSens also manufactures a range of fiber optic sensor products for medical devices and other critical, industrial applications. The acquisition of these products, Haemonetics said, fortifies its Hospital business portfolio in the interventional cardiology market. The company also said its Vascade vascular closure portfolio will .

OpSens还生产一系列用于医疗设备和其他关键工业应用的光纤传感器产品。Haemonetics表示，收购这些产品加强了其在介入心脏病学市场的医院业务组合。该公司还表示，其Vascade血管闭合组合将。。

'Expanding our Hospital portfolio with OpSens' products creates exciting growth and diversification opportunities, while providing immediately accretive financial benefits,' said Haemonetics' president and CEO Chris Simon. 'We are pleased to officially welcome OpSens to Haemonetics and look forward to driving greater access to OpSens' essential solutions and benefits for physicians and patients throughout the world.' .

Haemonetics总裁兼首席执行官克里斯·西蒙（ChrisSimon）说，用OpSens的产品扩大我们的医院投资组合，创造了令人兴奋的增长和多样化机会，同时提供了立竿见影的财务收益我们很高兴正式欢迎OpSens进入血液学，并期待着推动更多人获得OpSens的“全球医生和患者的基本解决方案和益处”。